Evidence map›Paper›PMID 21479980›Full record

ArticleInternational journal of hematology2011

Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.

Katsuhiro Miura, Hirotaka Takasaki, Hideki Tsujimura, Masatoshi Kanno, Yoshinobu Maeda, Naoto Tomita, Kazue Takai, Yasufumi Masaki, Jun Takizawa, Hiraku Mori and 4 more

Abstract readLetterMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Katsuhiro MiuraDepartment of Hematology and Rheumatology, Division of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo, Japan. javis@med.nihon-u.ac.jp.
Hirotaka TakasakiLymphoma Treatment Study Group, Nara, Japan.
Hideki TsujimuraLymphoma Treatment Study Group, Nara, Japan.
Masatoshi KannoLymphoma Treatment Study Group, Nara, Japan.
Yoshinobu MaedaLymphoma Treatment Study Group, Nara, Japan.
Naoto TomitaLymphoma Treatment Study Group, Nara, Japan.
Kazue TakaiLymphoma Treatment Study Group, Nara, Japan.
Yasufumi MasakiLymphoma Treatment Study Group, Nara, Japan.
Jun TakizawaLymphoma Treatment Study Group, Nara, Japan.
Hiraku MoriLymphoma Treatment Study Group, Nara, Japan.
Yasushi TerasakiLymphoma Treatment Study Group, Nara, Japan.
Takashi YoshidaLymphoma Treatment Study Group, Nara, Japan.
Jin TakeuchiDepartment of Hematology and Rheumatology, Division of Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi-ku, Tokyo, Japan.
Shigeki MotomuraLymphoma Treatment Study Group, Nara, Japan.
Nihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Stem Cell TransplantationAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsChromosome AberrationsClinical Trials as TopicCombined Modality TherapyCyclin D1CyclophosphamideDoxorubicinDrug Administration ScheduleFemaleHumansJapanKaryotypingAntibodies, Monoclonal, Murine-DerivedCyclin D1CyclophosphamideDoxorubicinPrednisoneRituximabVincristine

Identifiers

PMID21479980
OpenAlexW2040399235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.